DK3004353T3 - Bumetanid til behandling af neurodegenerative sygdomme med parkinson-syndromer - Google Patents

Bumetanid til behandling af neurodegenerative sygdomme med parkinson-syndromer Download PDF

Info

Publication number
DK3004353T3
DK3004353T3 DK14730466.1T DK14730466T DK3004353T3 DK 3004353 T3 DK3004353 T3 DK 3004353T3 DK 14730466 T DK14730466 T DK 14730466T DK 3004353 T3 DK3004353 T3 DK 3004353T3
Authority
DK
Denmark
Prior art keywords
bumetanid
treatment
neurodegenerative diseases
parkinson syndrome
parkinson
Prior art date
Application number
DK14730466.1T
Other languages
English (en)
Inventor
Yehezkel Ben-Ari
Nathalie Dehorter
Philippe Damier
Constance Hammond
Original Assignee
B & A Therapeutics Inmed
Ct Hospitalier Universitaire Nantes
Univ Aix Marseille
Univ Nantes
Inst Nat Sante Rech Med
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by B & A Therapeutics Inmed, Ct Hospitalier Universitaire Nantes, Univ Aix Marseille, Univ Nantes, Inst Nat Sante Rech Med filed Critical B & A Therapeutics Inmed
Application granted granted Critical
Publication of DK3004353T3 publication Critical patent/DK3004353T3/da

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/195Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/192Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/11DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1138Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
DK14730466.1T 2013-05-31 2014-05-28 Bumetanid til behandling af neurodegenerative sygdomme med parkinson-syndromer DK3004353T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP13170183.1A EP2808391A1 (en) 2013-05-31 2013-05-31 Modulators of intracellular chloride concentration for treating neurodegenerative diseases with parkinsonian syndromes
PCT/EP2014/061092 WO2014191471A1 (en) 2013-05-31 2014-05-28 Modulators of intracellular chloride concentration for treating neurodegenerative diseases with parkinsonian syndromes

Publications (1)

Publication Number Publication Date
DK3004353T3 true DK3004353T3 (da) 2019-06-17

Family

ID=48520848

Family Applications (1)

Application Number Title Priority Date Filing Date
DK14730466.1T DK3004353T3 (da) 2013-05-31 2014-05-28 Bumetanid til behandling af neurodegenerative sygdomme med parkinson-syndromer

Country Status (11)

Country Link
US (1) US9974763B2 (da)
EP (2) EP2808391A1 (da)
CA (1) CA2949910C (da)
DK (1) DK3004353T3 (da)
ES (1) ES2730023T3 (da)
HR (1) HRP20191030T1 (da)
HU (1) HUE045148T2 (da)
PL (1) PL3004353T3 (da)
PT (1) PT3004353T (da)
TR (1) TR201908928T4 (da)
WO (1) WO2014191471A1 (da)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3388520A1 (en) 2017-04-11 2018-10-17 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical composition for reducing the expression of nkcc1 in a subject in need thereof
EP3768251A4 (en) 2018-03-22 2022-12-07 Research Foundation Of The City University Of New York MODULATION OF NEURAL NKCC1 AS A THERAPEUTIC STRATEGY FOR SPASTICISM AND RELATED DISORDERS
US20210228519A1 (en) * 2018-04-12 2021-07-29 The Regents Of The University Of California Methods for treating apoe4/4-associated disorders
EP4051232A1 (en) 2019-10-31 2022-09-07 Neurochlore Liquid oral formulation of bumetanide
US20230390230A1 (en) * 2021-12-30 2023-12-07 Neuropro Therapeutics, Inc. Pharmaceutical composition
IT202200008057A1 (it) * 2022-04-22 2023-10-22 Fondazione St Italiano Tecnologia Modulatori della concentrazione intracellulare di cloruro per l'uso nel trattamento del declino cognitivo

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8008283B2 (en) 1998-12-23 2011-08-30 Neurotherapeutics Pharma, Inc. Methods and compositions for the treatment of neuropsychiatric disorders
WO2011133215A1 (en) * 2010-04-19 2011-10-27 Health Research Inc. Method of identifying and treating a person having a predisposition to or afflicted with parkinson disease
EP2598478A2 (en) * 2010-07-26 2013-06-05 Neurotherapeutics Pharma, Inc. Arylsulfonamide derivatives, compositions, and methods of use

Also Published As

Publication number Publication date
WO2014191471A1 (en) 2014-12-04
EP3004353A1 (en) 2016-04-13
TR201908928T4 (tr) 2019-07-22
PT3004353T (pt) 2019-06-18
CA2949910A1 (en) 2014-12-04
EP3004353B1 (en) 2019-04-10
CA2949910C (en) 2022-09-13
US20160106693A1 (en) 2016-04-21
EP2808391A1 (en) 2014-12-03
ES2730023T3 (es) 2019-11-07
HUE045148T2 (hu) 2019-12-30
PL3004353T3 (pl) 2019-10-31
US9974763B2 (en) 2018-05-22
HRP20191030T1 (hr) 2019-09-06

Similar Documents

Publication Publication Date Title
DK3076967T3 (da) Fremgangsmåder til behandling af residuelle symptomer på skizofreni
DK2983787T3 (da) Fremgangsmåde til behandling af posttraumatisk stresssygdom
DK2968208T3 (da) Behandling af kataplexi
DK3043816T3 (da) Anti-b7-h1-antistoffer til behandling af tumorer
DK3811943T3 (da) Forbindelse til anvendelse til behandling af øjenlidelser
DK3125875T3 (da) Inhalerbar rapamycinformulering til behandling af aldersrelaterede tilstande
DK2964315T3 (da) System til behandling af neuromotorisk dysfunktion
DK3030323T3 (da) Kdm1a-inhibitorer til behandlingen af sygdom
DK3033086T3 (da) Kombinationsterapi til behandling af cancer
DK2981255T3 (da) Terapeutiske anvendelser af empagliflozin
DK2961410T3 (da) Anvendelse af pyrazolopyrimidinderivater til behandlingen af pi3k relaterede lidelser
DK3035926T3 (da) Forbindelser og fremgangsmåder til behandling af en epilepsilidelse
DK3021838T3 (da) Behandling af fedme
DK2961388T3 (da) Kombinationer af lægemidler
DK3329884T3 (da) Implanterbar indretning til behandling af glaukom
DK3099298T3 (da) Kombinationsterapier med zidovudin til behandling af mikrobielle infektioner
DK3054976T3 (da) Anvendelse af semaphorin-4d-bindende molekyler til behandling af aterosklerose
DK3626270T3 (da) Behandling af kardiovaskulære sygdomme
DK3169328T3 (da) Quinolinderivater til behandling af inflammationssygdomme
DK3010895T3 (da) Fremgangsmåde til fremstilling af 4-propargyleret aminobenzoxazinoner
DK3007726T3 (da) Fremgangsmåder til behandling af en tauopati
DK3062811T3 (da) Angiopoietin-baserede interventioner til behandling af cerebral malaria
DK2976359T4 (da) Fremgangsmåder til behandling af osteogenesis imperfecta
DK3712264T3 (da) Cystathionin-beta-syntaseenzym til behandling af homocystinuri
DK3021839T3 (da) Sammensætninger for behandling af fibrose